首页> 美国卫生研究院文献>Blood Transfusion >Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better

【2h】

Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better

机译：血浆来源的重组凝血因子VIII浓缩物与A型血友病的浓缩物：血浆来源的更好

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

期刊名称 Blood Transfusion
作者
Pier Mannuccio Mannucci;
展开▼
作者单位

展开▼
年(卷),期 2010(8),4
年度 2010
页码 288–291
总页数 4
原文格式 PDF
正文语种
中图分类血液学检验;
关键词

相似文献

外文文献
中文文献
专利

1. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis [J] . Peyvandi F., Cannavo A., Garagiola I., Journal of thrombosis and haemostasis: JTH . 2018,第1期

机译：重组抑制剂抑制剂的时序和严重程度与血浆衍生因子VIII浓缩物：SIPPET分析
2. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: A critical systematic review [J] . FranchiniM., TagliaferriA., MengoliC., Critical reviews in oncology/hematology . 2012,第1期

机译：先前未经治疗的重度血友病患者中血浆衍生药物与重组凝血因子VIII浓缩物治疗的累积抑制剂发生率：一项重要的系统评价
3. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain [J] . Jimenez-YusteV., Nú?ezR., RomeroJ.A., Haemophilia: the official journal of the World Federation of Hemophilia . 2013,第6期

机译：重组活化因子VII与血浆来源的活化凝血酶原复合物浓缩物在西班牙重度A型血友病和抑制剂治疗中轻度至中度出血发作的成本效益
4. Development of a hyaluronic acid/plasma-derived fibrin hydrogel for the optimization of demo-epidermal autologous equivalents [C] . Jose Manuel Rey Legidos, Nieves Cubo Mateo, Andres Montero Simon, World biomaterials congress . 2016

机译：透明质酸/血浆纤维蛋白水凝胶的开发，用于优化表皮自体等效物
5. Carbohydrate structures of recombinant and human plasma-derived fibrinolytic and coagulation proteins. [D] . Brito-Robinson, Teresa. 1997

机译：重组和人血浆来源的纤溶和凝血蛋白的碳水化合物结构。
6. Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better [O] . Massimo Franchini 2010

机译：血浆衍生与重组凝血因子VIII浓缩物用于治疗A型血友病：重组更好
7. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort [O] . Valérie Gaboulaud, Armelle Parquet, Cedric Tahiri, 2002

机译：仅使用重组因子（F）VIII（F）vIII或至少一种等离子体衍生的FVIII或固定浓缩物（FRASE）（FRACE）对血友病儿童对人剖视性儿童的血液抗体B19的患病率：结果来自法国血友病队的结果
8. Utility of Human Plasma-Derived Butyrylcholinesterase (huBuChE) as a Therapeutic Measure in the Absence of Pre-Treatment or Conventional Post- Poisoning Therapies Against Nerve Agent [R] . Mumford, H. 2011

机译：人血浆衍生的丁酰胆碱酯酶（huBuChE）作为一种治疗措施的实用性，在没有预处理或常规的中毒后治疗神经毒剂的情况下

Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better

著录项

引文网络

相似文献

相关主题

期刊订阅